RT stock_family: U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy https://t.co/7qZbDq7WDC $PFE

🤟🤟🤟🤟 - https://t.co/YWb0YTEzG0 #options #stockmarket #daytrad…